HC Wainwright Sees Over 300% Upside In This Cancer-Focused Stock

  • HC Wainwright has initiated Theseus Pharmaceuticals Inc THRX with a Buy rating and a price target of $22 (310% upside).
  • The analysts see gastrointestinal stromal tumors (GISTs) treatment space reigniting with the entrance of a Theseus' pan-KIT inhibitor THE-630, with a high likelihood of 5L approval with earlier line potential. 
  • The analysts believe THE-630 can adequately tackle resistance in GIST by using dynamic molecular touchpoints that aim to ensure retention of inhibition.
  • Related: Analysts See Huge Upside In This Newly Listed Biopharma Stock.
  • HC Wainwright believes proprietary predictive resistance assay (PRA), a novel cell-based drug screening platform sets Theseus' approach apart.
  • THE-630 is currently being evaluated in a Phase 1 trial for GIST, with an initial readout expected in 1H23. 
  • The analysts are optimistic about THE-630 demonstrating preliminary objective response rate signals based on THE-630's performance in preclinical studies.
  • The analysts note that Theseus' PRA platform has already generated multiple promising tyrosine kinase inhibitor candidates for its EGFRi program, with a planned final nomination in 3Q22. 
  • Price Action: THRX shares are down 1.99% at $5.42 during the market session on the last check Friday.

Posted In: BriefsAnalyst ColorBiotechNewsHealth CarePrice TargetInitiationAnalyst RatingsGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.